| Patients with advanced liver cancer who were treated with sorafenib and doxorubicin lived twice as long those treated with doxorubicin alone, data from a phase II randomized study showed. Median overall survival increased from 6.5 months in patients on doxorubicin … Continue reading |
|
The post Liver cancer survival lengthened by sorafenib and doxorubicin appeared first on Health, Medical, and Science Updates.